The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...
A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.
Zacks Investment Research on MSN
Want better returns? Don't ignore these 2 medical stocks set to beat earnings
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. Life and ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Chocolate or strawberry? Life or death? We make some choices quickly and automatically, relying on mental shortcuts our brains have developed over the years to guide us in the best course of action.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback